← Back to Search

Decision-Making Tool for Ovarian Cancer

N/A

Recruiting

Led By Larissa Meyer, Meyer

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be able to understand, speak or read in Spanish

Patients must be individuals ≥ 18 years with advanced stage high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are receiving or have completed platinum-based chemotherapy for ovarian cancer and are potentially eligible to receive maintenance therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion; an average of 1 year.

Awards & highlights

Study Summary

This trial will create a tool to help Spanish-speaking patients make informed decisions about their medical care.

Who is the study for?

This trial is for Spanish-speaking individuals over 18 with advanced ovarian, fallopian tube, or primary peritoneal cancer who have had or are undergoing platinum-based chemotherapy and may receive maintenance therapy. Participants must understand Spanish. Eligible clinicians include MD Anderson gynecologic oncologists and providers at specific Houston locations.Check my eligibility

What is being tested?

The study aims to develop a tool that helps Spanish-speaking patients engage in shared decision-making regarding their maintenance therapy after initial treatment for ovarian cancer. It focuses on improving patient literacy and involvement in medical decisions.See study design

What are the potential side effects?

Since this trial is about creating a decision-making tool rather than testing a drug, there are no direct medical side effects involved. The focus is on communication and understanding of treatment options.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can understand, speak, or read Spanish.

Select...

I am 18 or older with advanced ovarian, fallopian tube, or peritoneal cancer and have completed or am receiving platinum-based chemotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion; an average of 1 year.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion; an average of 1 year.

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Decision Regret Scale questionnaire

Trial Design

2Treatment groups

Experimental Treatment

Group I: Study Phase 2Experimental Treatment3 Interventions

Usual Care (Control Group) or Participants utilize the Decision Support Tool with Provider guidance (Intervention Group).

Group II: Study Phase 1Experimental Treatment3 Interventions

Pre-testing and cognitive interviews for the Decision Support Tool

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor

3,892 Previous Clinical Trials

5,061,076 Total Patients Enrolled

41 Trials studying Ovarian Cancer

6,530 Patients Enrolled for Ovarian Cancer

M.D. Anderson Cancer CenterLead Sponsor

2,974 Previous Clinical Trials

1,789,326 Total Patients Enrolled

46 Trials studying Ovarian Cancer

16,675 Patients Enrolled for Ovarian Cancer

Larissa Meyer, MeyerPrincipal InvestigatorM.D. Anderson Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there slots available for this trial to participants?

"As of now, the clinical trial is recruiting participants. This research project was first uploaded to clinicaltrials.gov on August 31st 2023 and has been subsequently amended on September 21st 2023."

Answered by AI

What is the current enrollment rate for this medical research?

"Affirmative. Clinicaltrials.gov reveals that this medical experiment, which was unleashed on August 31st 2023, is currently in the process of recruitment. Approximately 70 patients must be found at a single site for participation in the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

2023. "Spanish Decision Tool for Ovarian Cancer Maintenance Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06036810.